2 results
Approved WMORecruiting
To assess the time to progression after TACE-DEB and after SBRT in a comparable population of patients diagnosed with HCC.
Approved WMOPending
Main objective:•To compare the progression-free survival of imlunestrant (Arm A) to the standard comparator of Investigator's Choice Endocrine Therapy of either fulvestrant or exemestane (Arm B) in the ITT population•To compare the PFS of Arm…